Articles On Botanix Pharmaceuticals (ASX:BOT)

Title Source Codes Date
Which ASX biotech shares are pioneering the future of medicine?

ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could...

Motley Fool BOT 2 days ago
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 2

Imricor has two upcoming pivotal trials and is looking to transform cardiac ablation procedures  Botanix Pharmaceuticals is expecting US FDA approval for its lead dermatology product Sofdra in late June Bell Potter is confident in Paradigm...

Stockhead BOT 3 weeks ago
“Your Stock Request” – 9 May 2024

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Fairmont Equities BOT 3 weeks ago
Could ASX cannabis shares be set for a smoking hot rebound?

With a few notable exceptions, ASX cannabis shares widely underperformed again over the last year. That's a far cry from the heady days of 2019 and 2020 when ASX cannabis shares joined their American-listed peers in setting investors' portf...

Motley Fool BOT 4 weeks ago
Weed Week: A VAST majority of Americans now want marijuana to be legal

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Stockhead BOT 1 month ago
Hot Money Monday: Momentum trading vs investing, and how both can profit using these 3 signals

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy takes the position that the stock market’s recent winners will remain winners. Note that there is a big difference between mome...

Stockhead BOT 1 month ago
“Your Stock Request” – 14 March 2024

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Fairmont Equities BOT 2 months ago
Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) Finishes its $13.5 million placement to accelerate its US commercial activities and to increase revenue turnaround The funds raised are for the commercial launch of Sofpironium Bromide gel, and the plac...

themarketherald.com.au BOT 5 months ago
Why are these 2 ASX cannabis stocks sputtering today?

Two ASX cannabis shares aren't joining in the broader market rally today. During the Tuesday lunch hour, the All Ordinaries Index (ASX: XAO) is up 0.5%. But cannabis stocks Little Green Pharma Ltd (ASX: LGP) and Botanix Pharmaceuticals Lt...

Motley Fool BOT 6 months ago
ScoPo’s Powerplays: Who fancies a ‘MedWalk intervention’? Oh, and ASX healthcare stocks can’t catch a break

ASX health sector falls in line with broader markets on macroeconomic factors and global geopolitical tensions Health imaging stock Volpara announces fourth consecutive quarter of operating cashflow Several ASX healthcare names with positi...

Stockhead BOT 7 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead BOT 8 months ago
TMH Market Close: Healthcare leads sectors as ASX200 slips half a per cent

The ASX200 closed the day down half a per cent. As far as the sector performances, healthcare was the clear leader, picking up a per cent and financials just scraped into positive territory. It was a big day for Strike Energy (STX) a...

themarketherald.com.au BOT 8 months ago
Botanix Pharmaceuticals (ASX:BOT) suffers setback in FDA approval for sofpironium bromide gel to treat hyperhidrosis

Botanix Pharmaceuticals’ (BOT) application to use sofpironium bromide gel to treat primary axillary hyperhidrosis has been knocked back by the US FDA A complete FDA review details key issues centred around the need for instructions to us...

themarketherald.com.au BOT 8 months ago
Why Botanix, Nick Scali, Resolute, and Sayona Mining shares are dropping

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. The benchmark index is currently down 0.5% to 7,042.6 points. Four ASX shares that are falling more than most today this week are lis...

Motley Fool BOT 8 months ago
ASX Health Stocks: Botanix Pharma plunges 25pc after FDA requests this minor change

US FDA requested Botanix to change its instructions paper Antisense says ATL1102 could be effective in muscular dystrophy Actinogen changes Phase 2b design to reduce cost and time to initial results   Botanix plunges after receiving FDA f...

Stockhead BOT 8 months ago
Top 10 at 11: It’s all about manganese, lithium and an overall sense of wellbeing and happiness

Stockhead’s Top 10 at shortly-before-11-ish, written through a red haze of blazing, sweary anger this morning because the guy who lives across the street has apparently got his leafblower back from having it repaired – after “someone” might...

Stockhead BOT 8 months ago
Guess which ASX cannabis share is crashing 36% following an FDA blow

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt and crashed deep into the red. In morning trade, the cannabis-focused ASX dermatology share is down a massive 36% to 11.5 cents. What's going on with...

Motley Fool BOT 8 months ago
ScoPo’s Powerplays: Who remembers that time they died? Oh, and Ramsay Healthcare cops credit downgrade

ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects...

Stockhead BOT 8 months ago
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?

Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks   Having been mauled fo...

Stockhead BOT 8 months ago
This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price hit a 52-week high of 21 cents this morning before giving back its gains and dropping into the red. When the ASX cannabis stock hit that level, it meant it was up a massive 160% since...

Motley Fool BOT 8 months ago
BOT ASX | Botanix Pharmaceuticals Ltd | Market Insights, News & Analysis | Livewire

Livewire BOT 8 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead BOT 8 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead BOT 9 months ago
New CEO to take the helm as PharmAust progresses clinical studies

New chief executive has experience executing clinical studies Dr Thurn was formerly part of the TGA’s Drug Safety Evaluation Branch Progress continues to be made on MND and canine cancer trials   PharmAust is strengthening its management...

Stockhead BOT 9 months ago
PharmAust (ASX:PAA) welcomes Dr Michael Thurn as new CEO

PharmAust (PAA) appoints Dr Michael Thurn as its newest CEO, effective September 1 The company reports he has extensive experience in drug discovery, regulation and clinical trials Dr Roger Aston will remain as Chair, but transition i...

themarketherald.com.au BOT 9 months ago
Botanix Pharmaceuticals elevates chief operating officer to CEO position

Botanix Pharmaceuticals (ASX: BOT) has announced that its chief operating officer has been appointed as its chief executive officer.

BiotechDispatch BOT 9 months ago
Botanix Pharmaceuticals (ASX:BOT) appoints Dr Howie McKibbon as CEO

Botanix Pharmaceuticals (BOT) appoints Dr Howie McKibbon as its newest CEO Dr McKibbon was previously Chief Operating Officer at the company He has more than 25 years of experience in the pharmaceutical industry and has led the launch...

themarketherald.com.au BOT 9 months ago
ASX Today: Stocks to watch on Friday

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower. A highly anticipated speech by the US Federal Reserve chairman on the state o...

themarketherald.com.au BOT 9 months ago
Market Highlights: Wall Street falls sharply as tech momentum fades; Betashares says build strong core first

Local shares set to open sharply lower on Friday Wall Street tumbled by over 1pc overnight as tech momentum faded Betashares says buy ETF for AI exposure   The ASX is set to open much lower this morning as the momentum on US tech stocks d...

Stockhead BOT 9 months ago
Weed Week: Mastercard says NO to cannabis transactions, as New York becomes the happening place for weed

Mastercard says no to weed transactions New York is where weed is happening Jeremy Buckingham pulls a stunt at NSW Parliament   Here’s a quick snapshot of cannabis news making headlines over the past week: Mastercard has told banks to sto...

Stockhead BOT 9 months ago
“Your Stock Request” – 3 August 2023

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Fairmont Equities BOT 9 months ago
Botanix Pharmaceuticals (ASX:BOT) completes $12.5m placement and royalty buyout

Botanix Pharmaceuticals (BOT) completes a $12.5 million placement and executes a buyout agreement for milestones and royalty payments for Sofpironium Bromide gel The company issues 104,166,667 new fully paid ordinary shares at 12 cents e...

themarketherald.com.au BOT 10 months ago
Botanix Pharmaceuticals secures $12.5m via an institutional placement

Botanix Pharmaceuticals has secured commitments from investors to raise up to $12.5 million via an institutional placement to fund the buyout of financial obligations owed to another company.

The West BOT 10 months ago
Botanix Pharmaceuticals (ASX:BOT) raises $12.5m to extinguish future milestone and royalty payments

Botanix Pharmaceuticals (BOT) raises $12.5 million through an institutional placement Funds will be used to extinguish future milestone and royalty payments related to Sofpironium Bromide The placement price of 12 cents per share repr...

themarketherald.com.au BOT 10 months ago
ScoPo’s (actually Wilkie’s) Powerplays: Inoviq soars on clinical data for breast cancer test

Clinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsay releases several announcements this week including possible sale of joint Asian venture Mach 7 expects significant cash collections in Q4...

Stockhead BOT 11 months ago
Weed Week: Storm before the calm as cannabis market set to boom after SAFE Banking Act passed

The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week   As we head into the...

Stockhead BOT 11 months ago
The Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreak

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Stockhead BOT 11 months ago
In Case You Missed It: Nickel finds, air compressors and high grade niobium

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead BOT 11 months ago
ASX Health Stocks: OncoSil to commence trial; Korea and Malaysia next stops for these biotechs

OncoSil gets Ethics committee approval Starpharma’s  nasal spray VIRALEZE granted approval in Malaysia Botanix Pharmaceuticals strikes deal in Korea   Medical device OncoSil Medical (ASX:OSL) rose 8% this morning after the Ethics committe...

Stockhead BOT 11 months ago
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

Stockhead BOT 1 year ago
MoneyTalks: Brokers see blue sky for these 3 ASX biotech stocks, with massive price targets

A handful of ASX biotechs are entering their crucial stages of development Promising outlooks for PharmAxis, Botanix Pharma, and Paragon Care   Pharmaxis could surge if FDA application successful Broker Taylor Collison sees an Outperform...

Stockhead BOT 1 year ago
Botanix secures investor commitments to progress its lead development program

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has secured commitments to raise $10 million that will be used to progress its lead development program.

BiotechDispatch BOT 1 year ago
Closing Bell: ASX climbs ahead of Australia’s Richest Morning Tea™ tomorrow at the RBA  

ASX 200 benchmark closes 0.5% higher, thanks to Energy surge.  XTX All Technology index has the batteries back in, up 1.26% for the day. Liontown farm-in huge news for E-I-E-I-Olympia Metals.   Local markets opened higher this morning (+0...

Stockhead BOT 1 year ago
Botanix Pharmaceuticals (ASX:BOT) passes FDA mid-cycle review for Sofpironium Bromide

Botanix Pharmaceuticals’ (BOT) lead product, Sofpironium Bromide, passes an FDA mid-cycle review The FDA detected no safety issues and no risk management issues or board requirements in the review of the Botanix product BOT says it wi...

themarketherald.com.au BOT 1 year ago
As it awaits crucial FDA approval Botanix reckons Aussies have a penchant for backing high-risk companies

Botanix Pharmaceuticals chief operating officer Dr Howie McKibbon believes Aussie Investors are comfortable backing early-stage, high-risk companies which is good for biotechs. When pitching an investment opportunity focused on a new drug...

Stockhead BOT 1 year ago
Closing Bell: ASX holds steady, Falcon flies on high grade gold hits

The ASX 200 was unchanged  The ASX XEC slips 0.38% 8 out of 11 sectors were higher lead by Information Technology   The ASX 200 was unchanged today and the ASX XEC was down 0.38%.  The index has lost 0.98% for the last five days, but sit...

Stockhead BOT 1 year ago
Botanix co-founder says interest from Pfizer for sweat-stopper gel is keeping him bullish ahead of FDA review

The co-founder of Botanix Pharmaceuticals says early interest from big industry players like Pfizer for the company’s gel aimed at treating excessive sweating was giving him confidence ahead of a key review. 

The West BOT 1 year ago
Tim Boreham’s 20 ASX stocks that are primed to run in 2023 – Part 2

Tim Boreham is one of Australia’s best-known small-cap share analysts and business journalists. He has more than 30 years of experience writing for major business publications.   After a rickety year dominated by the interest rate rises we...

Stockhead BOT 1 year ago
Botanix Pharmaceuticals (ASX:BOT) confirms US FDA NDA application formally under review

Botanix Pharmaceuticals (BOT) receives confirmation from the US FDA that its new drug application (NDA) for its sofpironium bromide product is formally in reviewThe FDA confirms it identified no filing review issues in the company’s NDA, an...

themarketherald.com.au BOT 1 year ago
Botanix Pharmaceuticals (ASX:BOT) placement and SPP raises just shy of $6m

Botanix Pharmaceuticals (BOT) has raised $5.96 million through a placement and share purchase plan (SPP)The company today reported its SPP, which closed last week, raised $960,000 — roughly a third of the $3 million soughtMeanwhile, the der...

themarketherald.com.au BOT 1 year ago